User:Xideral

Antonio E. Serrano Current

Department of Cell and Developmental Biology at University College London Past

Grad Student at Universidad de Chile Laboratory Manager at Antitumoral Immunity Laboratoy. Institute of Biomedical Sciences Medical Technologist. Pathology Service at Carabineer's Hospital

Education

Universidad de Chile

Xideral Public Profile

http://uk.linkedin.com/in/aeserrano

Publications

Interleukin 10 decreases MICA expression on melanoma cell surface. Immunology & Cell Biology August 17, 2010 Authors: Antonio E. Serrano, Evelyn Menares-Castillo, Macarena Garrido, Carolina H. Ribeiro, Caro Hernández, Ariadna Mendoza-Naranjo, Marcela Gatica-Andrades, Rodrigo Valenzuela, Roberto Zúñiga Olate, Mercedes Nitsche, MARIA CARMEN MOLINA

Natural-killer group 2, member D (NKG2D) binds to a variety of ligands, including the major histocompatibility complex (MHC) class I chain-related proteins (MIC) and UL16-binding proteins (ULBP). It is regarded as a co-activating receptor on NK cells, having an important role in the cell-mediated immune response to tumours. We studied the influence of interleukin (IL)-10 on the regulation of MIC... more Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy. Investigative Ophtalmology & Visual Science March 1, 2007 Authors: Antonio E. Serrano, Mercedes Nitsche, Cristian Pereda, Marcos Ramirez, Ariadna Mendoza-Naranjo, Arturo Ferreira, Rodrigo Poblete, Alexis Kalergis, Rolf Kiessling, Flavio Salazar-Onfray

purpose. Uveal melanoma is the most common primary malignant ocular cancer in adults. This tumor has a distinct expression pattern of markers compared with cutaneous melanoma. MC1R is under study as a potential target for antitumor immunity. Because of the potential immunogenicity of MC1R, it is important to evaluate its expression on uveal melanomas.Methods. Two novel monoclonal antibodies (MP1.... more   Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients        Clinical & Experimental Immunology        December 1, 2005    Authors: Antonio E. Serrano, Alejandro Escobar, Mercedes Nitsche, Marcos Ramirez, Claudio Perez, Adam Aguirre, Rodrigo Gonzalez, Jorge Alfaro, Milton Larrondo, Miguel Fodor, Flavio Salazar-Onfray

Dendritic cell (DC)-based therapy has proved to be effective in patients with a variety of malignancies. However, an optimal immunization protocol using DCs and the best means for delivering antigens has not yet been described. In this study, 20 patients with malignant melanoma in stages III or IV were vaccinated with autologous DCs pulsed with a melanoma cell lysate, alone or in combination with... more Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. British Journal of Cancer August 12, 2002 Authors: Antonio E. Serrano, Flavio Salazar-Onfray, Mercedes Nitsche, Andreas Lundqvist, Adam Aguirre, Alejandro Escobar, Caren Korenblit, Maria Petterson, Vijay Chhajlani, Olle Larsson, Rolf Kiessling

The melanocortin 1 receptor is a G-protein-coupled receptor, described to be expressed on melanomas and melanocytes. Subsequent RT–PCR studies demonstrated the presence of melanocortin 1 receptor mRNA in other tissues such as pituitary gland and testis. Previously, we have demonstrated that three HLA-A2 binding nonamer peptides derived from melanocortin 1 receptor can elicit peptide-specific CTL... more

Summary

PhD Biochemistry Medical Technologist. Bsc Medical Technology Specialties

Immunology